Cost analysis study comparing the impact of treatment with aprotinin versus tranexamic acid in cardiac surgery under cardiopulmonary bypass
Annales Pharmaceutiques Françaises · 2024
DOI: 10.1016/j.pharma.2024.07.005 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annales Pharmaceutiques Françaises, 2024. Verfasst von Clémence Huynh und 9 weiteren Autor:innen. Beteiligte Einrichtung: CHU de Bordeaux, unité de pharmacie clinique, service pharmacie à usage intérieur, avenue de Magellan, 33604 Pessac, France. Hauptthemen laut MEDLINE: Tranexamic Acid, Aprotinin, Antifibrinolytic Agents, Cardiac Surgical Procedures. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: An increased risk of mortality and postoperative side effects led to aprotinin (Trasylol®) withdrawal from the market in 2008, but since 2018 aprotinin has again been used in France. The French retrospective multicentre APACHE study (AProtinin versus tranexamic Acid in Cardiac surgery patients with High-risk for Excessive bleeding) compared the efficacy of tranexamic acid versus half-dose aprotinin. The aim of this study, ancillary to the APACHE study, is to carry out a medico-economic analysis of the use of these two antifibrinolytics on an APACHE subpopulation. METHODS: Economic data on reimbursement by the French health insurance system were extracted from the program for the data processing of medical information, and quantitative data on the cost of healthcare products were obtained from the hospital pharmacy software. RESULTS: The main analysis of costs for the population shows that the global valuation was not significantly different between the two treatment groups (P=0.60), but the costs of blood products included in the related hospital stay group (Groupe Homogène de séjour [GHS]) (whole blood, platelets and plasma) were higher for the tranexamic acid group (P=0.007). In a sub-analysis of patients alive at discharge, the costs of blood products in addition to GHS (blood-derived medicines) and the costs of blood products in the GHS were higher for the tranexamic acid group (P=0.04 and 0.001, respectively). CONCLUSIONS: The additional cost of aprotinin at the time of purchase is offset by the additional costs of blood products in the tranexamic acid group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CHU de Bordeaux, unité de pharmacie clinique, service pharmacie à usage intérieur, avenue de Magellan, 33604 Pessac, France.
- Service d'information médicale, pôle de santé publique, place Amélie-Raba-Leon, 33000 Bordeaux, France.
- CHU de Bordeaux, centre de pharmacovigilance, pharmacologie médicale, place Amélie-Raba-Leon, 33000 Bordeaux, France; Université Bordeaux, Inserm Bordeaux Population Health Research Center team Pharmacoepidemiology, UMR…
- CHU de Bordeaux, unité de coordination et d'analyse de l'information médicale (DIM), service d'information médicale, pôle de santé publique, place Amélie-Raba-Leon, 33000 Bordeaux, France.
- CHU de Bordeaux, service d'hémovigilance et de sécurité transfusionnelle, avenue de Magellan, 33604 Pessac, France.
- CHU de Bordeaux, department of Cardiovascular Anaesthesia and Critical Care, 33000 Bordeaux, France.
Zitieren
APA
Huynh, C., Crubezy, I., Trin, K., Perino, J., Ong, N., Ramaroson, H., Puntous, M., Gallo, E., Ouattara, A., & Xuereb, F. (2024). Cost analysis study comparing the impact of treatment with aprotinin versus tranexamic acid in cardiac surgery under cardiopulmonary bypass. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2024.07.005
Vancouver
Huynh C, Crubezy I, Trin K, Perino J, Ong N, Ramaroson H, et al. Cost analysis study comparing the impact of treatment with aprotinin versus tranexamic acid in cardiac surgery under cardiopulmonary bypass. Annales Pharmaceutiques Françaises. 2024. doi:10.1016/j.pharma.2024.07.005
BibTeX
@article{Huynh2024,
author = {Huynh, Clémence and Crubezy, Isabelle and Trin, Kilian and Perino, Justine and Ong, Nathalie and Ramaroson, Hanta and Puntous, Maryse and Gallo, Eloise and Ouattara, Alexandre and Xuereb, Fabien},
title = {Cost analysis study comparing the impact of treatment with aprotinin versus tranexamic acid in cardiac surgery under cardiopulmonary bypass},
journal = {Annales Pharmaceutiques Françaises},
year = {2024},
doi = {10.1016/j.pharma.2024.07.005}
}
EUVIMED